AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15189589 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal structure of PSTs
Number of subjects: 0
Study 10785873 — intervention group
Group type: EXPERIMENTAL
Intervention: LpL activity in non-obese individuals
Number of subjects: 83
Study 10785873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic lipase activity in non-obese individuals
Number of subjects: 83
Study 10785873 — intervention group
Group type: EXPERIMENTAL
Intervention: LpL activity in obese individuals
Number of subjects: 83
Study 8810625 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lavage
Number of subjects: 5
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 618
Study 1452917 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 618
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (anterior infarction)
Number of subjects: 618
Study 1452917 — intervention group
Group type: COMPARATOR
Intervention: Control group (anterior infarction)
Number of subjects: 618
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (inferior infarction)
Number of subjects: 618
Study 1452917 — intervention group
Group type: COMPARATOR
Intervention: Control group (inferior infarction)
Number of subjects: 618
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase therapy
Number of subjects: 618
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction and thallium-201 infarct size
Number of subjects: 618
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 618
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 618
Study 1452917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior myocardial infarction
Number of subjects: 618
Study 2982266 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.4 mg/hr for 3 hours)
Number of subjects: 7
Study 29327649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dive training with auditory components (speaker and electronic horn)
Number of subjects: 10
Study 29327649 — intervention group
Group type: COMPARATOR
Intervention: Dive training without auditory components
Number of subjects: 10
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (TE), sulfamethoxazole (STX), and ampicillin (AMP) resistant coliforms
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) resistant coliforms
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX-resistant coliforms in humans
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli resistance rates
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiresistant isolates
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX-resistant isolates
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP- and vancomycin-resistant enterococci
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococci resistance
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: sulII gene copies
Number of subjects: 485
Study 28759321 — intervention group
Group type: EXPERIMENTAL
Intervention: tetW genes in cattle vs humans
Number of subjects: 485
Study 27236772 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice per day (b.i.d.) with dose titration
Number of subjects: 213
Study 27236772 — intervention group
Group type: COMPARATOR
Intervention: Placebo titration
Number of subjects: 213
Study 27236772 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg b.i.d. (nonrandomized patients)
Number of subjects: 213
Study 24094565 — intervention group
Group type: EXPERIMENTAL
Intervention: CSI-guided control of anesthetic depth
Number of subjects: 50
Study 24094565 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical monitoring of anesthetic depth)
Number of subjects: 50
Study 22466511 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valves treatment
Number of subjects: 289
Study 22466511 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 289
Study 21250569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic resin polymerized by long cycle with added 2% PTFE
Number of subjects: 40
Study 21250569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic resin polymerized by short cycle with added 2% PTFE
Number of subjects: 40
Study 21250569 — intervention group
Group type: COMPARATOR
Intervention: Acrylic resin polymerized by long cycle
Number of subjects: 40
Study 21250569 — intervention group
Group type: COMPARATOR
Intervention: Acrylic resin polymerized by short cycle
Number of subjects: 40
Study 19025646 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 58
Study 16115790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonomyography (SMG) using a portable B-mode ultrasound scanner
Number of subjects: 9
Study 16115790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonomyography (SMG) signals from residual forearms
Number of subjects: 9
Study 12515575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (DMSO)
Number of subjects: 131
Study 12515575 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 131
Study 12515575 — intervention group
Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 131
Study 10613428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only (DO, N = 9)
Number of subjects: 29
Study 10613428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and aerobic exercise (DE, N = 9)
Number of subjects: 29
Study 10613428 — intervention group
Group type: COMPARATOR
Intervention: Control (C, N = 11)
Number of subjects: 29
Study 10613428 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study 7802571 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (1 g of cephalothin sodium intravenously 30 minutes before the procedure and 500 mg of cephalexin orally every 6 hours for 3 days after the procedure)
Number of subjects: 164
Study 7802571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic therapy)
Number of subjects: 164
Study 2086420 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-927 (1% and 2%)
Number of subjects: 20
Study 2086420 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-417 (1% and 1.8%)
Number of subjects: 20
Study 2086420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 353833 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (2 g) + oxprenolol (80 mg)
Number of subjects: 6
Study 353833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31172867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer monitoring of upper limb exercise program
Number of subjects: 10
Study 31331372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT) set at 37°C and 60 L/min
Number of subjects: 80
Study 31331372 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV) applied through a mask with pressure support mode, PEEP set at 3-5 cmH2O, tidal volume between 6-8 ml/kg
Number of subjects: 80
Study 27223809 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. for 12 weeks
Number of subjects: 323
Study 27223809 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 323
Study 27223809 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 323
Study 26110625 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training included in pulmonary rehabilitation (3 times a week for 6 months)
Number of subjects: 62
Study 26110625 — intervention group
Group type: COMPARATOR
Intervention: PR-only group (standard pulmonary rehabilitation for 6 months)
Number of subjects: 62
Study 23201103 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards supraannular aortic valve (CE‐SAV)
Number of subjects: 403
Study 23201103 — intervention group
Group type: COMPARATOR
Intervention: Mosaic aortic prosthesis
Number of subjects: 403
Study 21943027 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (low-dose)
Number of subjects: 334
Study 21943027 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (medium-dose)
Number of subjects: 334
Study 21943027 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (high-dose)
Number of subjects: 334
Study 21943027 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Control)
Number of subjects: 334
Study 17616470 — intervention group
Group type: EXPERIMENTAL
Intervention: High dissociators
Number of subjects: 100
Study 17616470 — intervention group
Group type: COMPARATOR
Intervention: Low dissociators
Number of subjects: 100
Study 17616470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 17616470 — intervention group
Group type: EXPERIMENTAL
Intervention: High and low dissociators
Number of subjects: 100
Study 16929627 — intervention group
Group type: EXPERIMENTAL
Intervention: Oralized deaf individuals
Number of subjects: 24
Study 16929627 — intervention group
Group type: COMPARATOR
Intervention: Normal listening individuals
Number of subjects: 24
Study 16929627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during clinical activities of mastication and dental compression
Number of subjects: 24
Study 12620524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate oral supplement (16.7% protein, 55.1% fat, 28.2% CHO)
Number of subjects: 60
Study 12620524 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (15% protein, 20% to 30% fat, and 60% to 70% CHO)
Number of subjects: 60
Study 11181997 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC plus vinorelbine (days 1 and 8, q 21 days for up to six cycles)
Number of subjects: 191
Study 11181997 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 191
Study 11181997 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC plus vinorelbine
Number of subjects: 191
Study 9926766 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 10
Study 9926766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket reduction through osseous surgery and apically‐positioned flap
Number of subjects: 10
Study 9926766 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap
Number of subjects: 10
Study 9926766 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap and topical application of saturated citric acid at pH 1 for 3 minutes
Number of subjects: 10
Study 9926766 — intervention group
Group type: COMPARATOR
Intervention: All treatment modalities
Number of subjects: 10
Study 11271288 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium lactobionate/raffinose solution
Number of subjects: 40
Study 11271288 — intervention group
Group type: COMPARATOR
Intervention: High-potassium lactobionate/raffinose solution
Number of subjects: 40
Study 2740166 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly home visiting
Number of subjects: 210
Study 2740166 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly home visiting
Number of subjects: 210
Study 2740166 — intervention group
Group type: COMPARATOR
Intervention: Monthly home visiting
Number of subjects: 210
Study 2740166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visiting)
Number of subjects: 210
Study 8031165 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT administration
Number of subjects: 98
Study 8031165 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU administration
Number of subjects: 98
Study 377539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin and clindamycin
Number of subjects: 59
Study 377539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 29373042 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched message
Number of subjects: 602
Study 29373042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatched message
Number of subjects: 602
Study 29373042 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 602
Study 29373042 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive group
Number of subjects: 602
Study 29373042 — intervention group
Group type: EXPERIMENTAL
Intervention: Indifferent group
Number of subjects: 602
Study 30241686 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g of n3 FAs
Number of subjects: 440
Study 27107672 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30-270mg/d)
Number of subjects: 0
Study 27107672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24784698 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (200 μg, bid)
Number of subjects: 138
Study 24784698 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (4 mg, bid)
Number of subjects: 138
Study 24784698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 23077861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat)
Number of subjects: 105
Study 23077861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 18839053 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day)
Number of subjects: 34
Study 18839053 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes only
Number of subjects: 34
Study 16893493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 30
Study 15236888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusafungine plus analgesic (acetaminophen)
Number of subjects: 60
Study 15236888 — intervention group
Group type: EXPERIMENTAL
Intervention: Only fusafungine
Number of subjects: 60
Study 15236888 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic (amoxicillin‐clavulanic acid) plus analgesic (acetaminophen)
Number of subjects: 60
Study 11943263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 11943263 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy + Tamoxifen
Number of subjects: 0
Study 11943263 — intervention group
Group type: COMPARATOR
Intervention: Control (never-users of hormone replacement therapy)
Number of subjects: 0
Study 9810148 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min nap
Number of subjects: 30
Study 9810148 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-min nap
Number of subjects: 30
Study 9810148 — intervention group
Group type: COMPARATOR
Intervention: No-nap
Number of subjects: 30
Study 8129156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 1637
Study 8129156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1637
Study 8129156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg and 8 mg (combined analysis)
Number of subjects: 1637
Study 8129156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (study 3)
Number of subjects: 1637
Study 8129156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study 2757151 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with adrenaline 1:200,000 (pH 3.9) 2 mg/kg
Number of subjects: 24
Study 2757151 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinised bupivacaine with adrenaline 1:200,000 (pH 6.4) 2 mg/kg
Number of subjects: 24
Study 769506 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 400 mg daily
Number of subjects: 0
Study 769506 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg daily
Number of subjects: 0
Study 769506 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg daily with pemoline 20 mg daily
Number of subjects: 0
Study 769506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31310990 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT+WB
Number of subjects: 25
Study 31310990 — intervention group
Group type: COMPARATOR
Intervention: SIT
Number of subjects: 25
Study 31310990 — intervention group
Group type: COMPARATOR
Intervention: EX+SIT
Number of subjects: 25
Study 29084960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency transcranial electrical stimulation (tACS)
Number of subjects: 0
Study 29084960 — intervention group
Group type: COMPARATOR
Intervention: Positive controls (endogenous slow-wave activity and rhythmic noise-burst acoustic stimulation)
Number of subjects: 0
Study 25752972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 336
Study 23369360 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging (LDI)
Number of subjects: 200
Study 23369360 — intervention group
Group type: COMPARATOR
Intervention: Current diagnostic strategy
Number of subjects: 200
Study 22022584 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) treatment
Number of subjects: 944
Study 22022584 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (40 µg) PTH (1-34)
Number of subjects: 944
Study 22022584 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH treatment
Number of subjects: 944
Study 19318676 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐cell interferon (IFN)‐gamma release blood assay T‐SPOT.TB (TS.TB)
Number of subjects: 331
Study 19318676 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON‐TB Gold In‐Tube (QFT‐IT)
Number of subjects: 331
Study 19318676 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 331
Study 19318676 — intervention group
Group type: COMPARATOR
Intervention: TST
Number of subjects: 331
Study 19318676 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT‐IT
Number of subjects: 331
Study 16954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain group (n = 101)
Number of subjects: 198
Study 16954994 — intervention group
Group type: COMPARATOR
Intervention: No-drain group (n = 97)
Number of subjects: 198
Study 16285323 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (previous treatment)
Number of subjects: 23
Study 16285323 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of topical corticosteroids and gradual reduction of skin-care products
Number of subjects: 23
Study 16285323 — intervention group
Group type: COMPARATOR
Intervention: Face-care or eye-care products usage
Number of subjects: 23
Study 16285323 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to healing
Number of subjects: 23
Study 16285323 — intervention group
Group type: COMPARATOR
Intervention: History of atopic diseases and reactive prick tests
Number of subjects: 23
Study 10970915 — intervention group
Group type: COMPARATOR
Intervention: St. John's wort
Number of subjects: 40
Study 10970915 — intervention group
Group type: COMPARATOR
Intervention: Kava
Number of subjects: 40
Study 10970915 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 40
Study 10970915 — intervention group
Group type: COMPARATOR
Intervention: Valerian
Number of subjects: 40
Study 9486442 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewed group (n = 42)
Number of subjects: 80
Study 9486442 — intervention group
Group type: COMPARATOR
Intervention: Not reviewed group (n = 38)
Number of subjects: 80
Study 8179563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 mcg/kg iv)
Number of subjects: 55
Study 8179563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg im)
Number of subjects: 55
Study 3953214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams of dicloxacillin as an intravenous infusion at the induction of anaesthesia
Number of subjects: 21
Study 3953214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams of dicloxacillin as an intravenous infusion 3 hours before surgery
Number of subjects: 21
Study 3953214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams of dicloxacillin as an intravenous infusion approximately 6 hours before surgery
Number of subjects: 21
Study 29888581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (2 Hz/100 Hz, 4‐8 mA) applied to specific acupuncture points, 3 times a week for 12 weeks
Number of subjects: 58
Study 29888581 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet control and aerobic exercise, 3 times a week for 12 weeks)
Number of subjects: 58
Study 28622156 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training of 30 min three to five times per week
Number of subjects: 75
Study 28622156 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training five times weekly (two contractions of 2 min at 30% of maximal power with each arm)
Number of subjects: 75
Study 28622156 — intervention group
Group type: COMPARATOR
Intervention: Sham-handgrip training five times weekly (two contractions of 2 min at 5% of maximal power with each arm)
Number of subjects: 75
Study 25088860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 88
Study 25088860 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 88
Study 25088860 — intervention group
Group type: COMPARATOR
Intervention: Trocar site infiltration of bupivacaine
Number of subjects: 88
Study 22890495 — intervention group
Group type: EXPERIMENTAL
Intervention: PLP training at high frequency (2.5 Hz)
Number of subjects: 30
Study 22890495 — intervention group
Group type: EXPERIMENTAL
Intervention: PLP training at low frequency (0.5 Hz)
Number of subjects: 30
Study 22890495 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance training (0.5 Hz)
Number of subjects: 30
Study 21143686 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including a personalized report, booklet on alcohol and aging, drinking diary, advice from the primary care provider, and telephone counseling from a health educator at 2, 4, and 8 weeks.
Number of subjects: 631
Study 21143686 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention
Number of subjects: 631